SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
September
14, 2023
Commission
File Number 001-14978
SMITH & NEPHEW plc
(Registrant's
name)
Building 5, Croxley Park,
Hatters Lane, Watford, Hertfordshire, WD18 8YE,
England
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Appointment of Non-Executive Directors and Confirmation of
Chair
14 September 2023
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology
company, announces the following Board appointments.
The Company is pleased to announce
that Jeremy (Jez) Maiden and Simon Lowth will be joining the Board
as independent Non-Executive Directors. Jez joins today and will
serve as a member of the Audit Committee and Remuneration
Committee. Simon will join on 1 January 2024 and will serve as a
member of the Audit Committee and Nomination & Governance
Committee.
Additionally, Rupert
Soames will, as planned, assume
the role as Chair of the Board on 15 September, in succession to
Roberto Quarta. Rupert has also been appointed as Chair of the
Nomination & Governance Committee and will continue to serve on
the Remuneration Committee.
Jez Maiden has extensive global financial experience across a
diverse range of industries and sectors. He retired earlier this
year as Group Finance Director at Croda International, the FTSE-100
global speciality chemicals company, and before that held similar
roles at National Express Group and Northern Foods. He is currently
Senior Independent Director at Travis Perkins plc and a
Non-Executive Director and member of the Audit Committee at
Intertek Group plc. Previously, he served as the Senior Independent
Director at Synthomer and at both PZ Cussons and Synthomer he
chaired the Audit Committee and served on the Remuneration
Committee. He is a fellow of the Chartered Institute of Management
Accountants.
Simon Lowth has
deep experience in finance, accounting, risk, corporate strategy as
well as mergers and acquisitions. He
currently serves as Group Chief Financial officer of BT Group, a
role he has held since 2016 and previously performed the same role
at BG Group, AstraZeneca and Scottish Power. Before
joining Scottish Power, he led the Industrial Practice of McKinsey
in the UK and has a background in engineering. He previously served
as a Non-Executive Director on the Board of Standard Chartered. He
currently holds no additional external
appointments.
Rupert Soames commented:
"We are delighted to be able to announce two such strong
appointments to our Board. Simon and Jez bring deep executive and
non-executive experience of serving on boards of companies which
have had to address strategic and operational challenges across a
number of different industries, including life-sciences and
healthcare. They both have experience of supervising large
operations in the US, Europe and Asia and of working in
highly-regulated industries.
"Simon brings a wealth of expertise across a wide range of sectors,
including within regulated industries. Having served as the CFO in
four FTSE-100 companies, including AstraZeneca and, currently, BT,
he has deep experience of capital markets, implementing strategic
change, cost transformation and performance improvement programmes
as well as understanding how technology can be used to transform a
business, all of which will be very helpful to the
Board.
"Jez brings more than 15 years of experience both as a FTSE Chief
Financial Officer and as a Non-Executive Director in businesses
involved in manufacturing, science and technology and will be a
valuable addition to the Board and its Committees.
"Finally, I want to pay tribute to my predecessor Roberto Quarta
who has delivered great service to the Company since taking over as
Chair of Smith & Nephew in 2014. He has shown immense diligence
and skill leading the Board and helping to navigate the company
through challenging times; my colleagues on the Board and across
the business are grateful for his leadership and
commitment."
No disclosure obligations arise under paragraphs (1) to (6) of LR
9.6.13 R of the UK Listing Authority's Listing Rules in respect of
the two new appointments. In line with current Non-Executive
Directors, Jez Maiden and Simon Lowth will each be paid annual fees
of £69,500, of which £6,500 will be paid in Smith+Nephew
shares.
Enquiries
|
Investors / Analysts
Andrew SwiftSmith+Nephew
|
+44 (0) 1923 477433
|
|
Media
Charles ReynoldsSmith+Nephew
|
+44 (0) 1923 477314
|
|
Susan Gilchrist / Ayesha BharmalBrunswick
|
+44 (0) 20 7404 5959
|
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 19,000 employees deliver this mission every
day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new
technologies across our three global franchises of Orthopaedics,
Advanced Wound Management and Sports Medicine &
ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading profit margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of Covid, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
Covid; economic and financial conditions in the markets we serve,
especially those affecting healthcare providers, payers and
customers (including, without limitation, as a result of Covid);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal and financial compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers (including, without limitation, as a result of Covid);
competition for qualified personnel; strategic actions, including
acquisitions and disposals, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments;
relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to
natural disasters, weather and climate change related events;
changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC's website at www. sec.gov, for
a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of
the date of the statement. All written or oral forward-looking
statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update
or revise any forward-looking statement to reflect any change in
circumstances or in Smith+Nephew's expectations.
◊ Trademark
of Smith+Nephew. Certain marks registered in US Patent and
Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: September
14, 2023
By: /s/
Helen Barraclough
-----------------
Helen
Barraclough
Company
Secretary
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Apr 2024 to May 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From May 2023 to May 2024
